Background: Prostate cancer (PC) is a complex, multi-factorial disease. In spite of its high prevalence, the Pathophysiology of thePC progression is poorly understood. Cytokines play important role in immune regulation. Cytokines (IL-6) regulates growth ofmany tumor cells including prostate cancer, therefor it can be used as a marker for PC.Objectives: To measure and compare the levels of IL-6 between metastatic and non- metastatic prostate cancer patients.Material and Methods: This study was a Cross-sectional analytical and was conducted in the Department of physiology FederalPsotgraduate Medical Institute (FPGMI) Lahore with collaboration of Urology department of Sheikh Zayed hospital Lahore.Patients with prostate cancer registered with Urology department, Sheikh Zayed Hospital Lahore were recruited for the study.Patients with inflammatory conditions, auto-immune diseases, obesity and Alzimer's disease were excluded. A standard Elisa kit(Thermo scientific made in USA) was used for estimation of serum IL-6 levels. Data was recorded on a structured checklist, whichcontained basic demographic data along with finding of prostate specific antigen (PSA), prostatic biopsy, bone scan and serum IL-6levels. Data was analyzed through SPSS version 20 for descriptive statistics.Results: A total of 50 (25 metastatic and 25 non-metastatic) prostate cancer patients were being part of the present study. Themean PSA level was 364.42 ± 86.7 among metastatic prostate cancer patients as compared to 30.71 ±23.48 non- metastatic,indicating significant difference (p =0.001). Similarly mean Gleason score was high (7.16±0.85) among metastatic prostate cancerpatients as compared to 6.28±0.54 among non-metastatic one. Significant difference (p=0.014) was observed regarding IL-6. Itwas 25.73±80.48 among metastatic patients in comparison with 1.56±1.38 among non-metastatic patients. There was strongcorrelation between PSA and Gleason score (r= 0.479**, p<0.001). Also positive association was found between IL-6 and PSA, (r=0.285*, p=0.045).Conclusion: Serum IL-6 might be considered as a predictor for metastatic prostate cancer. Along with PSA, serum IL-6 levelscould be a strong predictor for the diagnosis of metastatic condition of prostate cancer.